insights_auto
Why is OPHLY up 6,24%?
Dive Deeperchevron_right
OPHLY:OTCMKTS
Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
US$4,94
arrow_upward
+6,24%(+0,29) 1D
15 ຕ.ລ., 10 ໂມງ 28 ນາທີ 59 ວິນາທີ GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for OPHLY...
Open
US$4,96
High
US$4,96
Low
US$4,94
Mkt. cap
1,17 ລ້ານລ້ານ
Avg. vol.
61,54 ພັນ
Volume
6,51 ພັນ
52-wk high
US$5,75
52-wk low
US$3,82
Beta
0,21
Shares outstanding
1,50 ຕື້
No. of employees
4 ພັນ
Open
US$4,96
High
US$4,96
Low
US$4,94
Mkt. cap
1,17 ລ້ານລ້ານ
Avg. vol.
61,54 ພັນ
Volume
6,51 ພັນ
52-wk high
US$5,75
52-wk low
US$3,82
Beta
0,21
Shares outstanding
1,50 ຕື້
No. of employees
4 ພັນ
News stories
From web sources and news partners
www.foreignpolicyjournal.com
·
10 ນາທີກ່ອນ
Lululemon Athletica (NASDAQ: LULU) Restructures Fabric Team Following String Of Product Quality Failures
bloomingbit
·
47 ນາທີກ່ອນ
Nasdaq-Listed Tron Files $200 Million Stock Offering to Fund TRX Purchases
CNN
·
4 ຊົ່ວໂມງກ່ອນ
Global tech sell-off deepens as enthusiasm for AI stocks wobbles
Reuters
·
4 ຊົ່ວໂມງກ່ອນ
S&P 500's march to 8,000 hinges on 'very, very strong' third quarter
Profile
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
About Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
CEOGyo Sagara | Gyo Sagara
Employees4,21 ພັນ
Founded1717
HeadquartersOsaka, Osaka, ຍີ່ປຸ່ນ
SectorPharmaceutical industry
Websiteono-pharma.com